S44 One Fell Swoop: Ozanimod for Ulcerative Colitis and Multiple Sclerosis

Abstract

vaccine recipients. Vaccination with a non-mRNA vaccine predicted lower antibody levels (beta: -5.90 [95% CI: -6.99 to -4.82]; P , 0.0001) and less seroconversion (Fisher's exact: P , 0.0001), whereas age, sex, body mass index, and absolute lymphocyte count (ALC) did not predict lower antibody levels in nucleocapsid antibody-negative participants. Conclusion(s): Participants receiving ozanimod developed humoral immune response to SARS-CoV-2 vaccines, with 100% seroconversion after mRNA vaccination; this was independent of demographic characteristics and ALC levels at time of vaccination. However, some participants developed low antibody concentrations and may benefit from booster doses. Fully vaccinated participants with confirmed evidence of natural infection had higher seroconversion rates and RBD antibody levels, possibly suggesting a primed immune response.